Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Charles River Laboratories Intl. Inc (CRL) vs JD.Com Inc (JD) Price & Performance

Charles River Laboratories Intl. IncTrade
JD.Com IncTrade

Price performance (Past 24H)

Key statistics

Charles River Laboratories Intl. Inc vs JD.Com Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $286.79 (market cap $13.46B), while JD.Com Inc trades at $31.49 (market cap $44.04B). The key difference: JD.Com Inc is far larger — about 3.3× Charles River Laboratories Intl. Inc's market cap, and JD.Com Inc pays a 3.13% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.

CRLJD
Market Cap
$13.46B$44.04B
Sector
HealthConsumer Cyclical
52-Week High
$282.00$36.17
52-Week Low
$145.57$25.19
Enterprise Value
$16.30B$30.10B
Dividend Yield
3.13%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Charles River Laboratories Intl. Inc

Charles River Laboratories (CRL) trades at $286.36, up 3.38% today and near its 52-week high of $277.07. The stock shows strong technical momentum with bullish moving averages and has beaten earnings estimates for three consecutive quarters. Recent Q2 2026 results exceeded expectations with EPS of $3.02 versus $2.77 estimate, driving positive sentiment. However, valuation metrics remain elevated with P/E at 684.85 and negative profitability margins.

While technical indicators and analyst consensus (72% buy ratings) support near-term upside, fundamental concerns persist with negative net income margin (-5.96%) and ROE (-7.7%). The stock faces execution risks in maintaining earnings momentum amid competitive pressures. Current price exceeds consensus target of $277.29, suggesting limited near-term upside potential despite positive business inflection.

JD.Com Inc

JD stock trades at $31.29, down 6.51% over 24 hours, amid broader pressure on Chinese equities. The company reported strong Q1 2026 earnings, beating estimates with EPS of $0.74 versus $0.57 expected, while revenue grew to $1.31 trillion in 2025. Technical indicators show a bullish overall signal, with RSI at 28.66 suggesting potential oversold conditions. Analyst consensus remains strongly bullish with a $38.00 price target.

The outlook is positive given earnings beats and low valuation multiples like P/S of 0.24, but risks include regulatory scrutiny from the EU over the Ceconomy deal and margin pressures from expansion costs. Upside potential exists if Q2 results on August 13, 2026, exceed expectations, though macroeconomic headwinds for Chinese stocks pose a near-term challenge.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Charles River Laboratories Intl. Inc

Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.

Read more on CRL

About JD.Com Inc

JD.com is China's second-largest e-commerce company after Alibaba in terms of gross merchandise volume, offering a wide selection of authentic products at competitive prices, with speedy and reliable delivery. The company has built its own nationwide fulfilment infrastructure and last-mile delivery network, staffed by its own employees, which supports both its online direct sales, its online marketplace and omnichannel businesses.

Read more on JD